Moderna (MRNA) shares are giving back some of their recent gains on Thursday, but the spotlight remains on Merck (MRK) after a Morgan Stanley analyst reiterated a bullish stance following promising cancer trial results.
The optimism stems from a late-stage study showing that a combination of Moderna's investigational therapy, intismeran autogene, and Merck's blockbuster drug Keytruda significantly improved outcomes in high-risk melanoma patients. The data has reinforced confidence in Merck's oncology franchise, prompting analyst Terence Flynn to set a price target of $179 on MRK shares.
Flynn's upgrade to Overweight comes despite Merck's stock already surging roughly 45% year-to-date in 2026. The analyst argues that concerns over Keytruda's patent expiration in 2028 are overblown, as the company's pipeline—including intismeran autogene, sac-TMT, and tulisokibart for inflammatory bowel disease—can bridge the revenue gap. He also highlights strategic co-formulations that could extend Keytruda's market life.
Merck's financial strength is another pillar of the bullish thesis. Keytruda alone generated over $16 billion in revenue during the first half of 2026, providing ample cash flow for R&D and potential acquisitions. The company also pays a healthy dividend yield of 2.27%, making it attractive to income-focused investors.
From a technical perspective, Merck's recent rally has pushed the stock above its 20-day moving average, signaling sustained bullish momentum. The breakout on heavy volume suggests institutional accumulation, even as some near-term consolidation is possible after such a steep climb.
Wall Street's consensus remains firmly in the buy camp, with most brokerages rating MRK as Overweight or Buy. The stock trades at a price-to-sales multiple of under 6x, a significant discount to its historical average, which could offer further upside as new therapies come to market.
Investors should note that Moderna's recent surge was driven by the same trial data, but the stock has since pared gains. Meanwhile, broader market reactions have been mixed, with some investors rotating into safer assets.
Merck's robust pipeline and financial flexibility position it well for long-term growth, even as the market digests the implications of Keytruda's eventual loss of exclusivity. The company's ability to generate consistent cash flow and return capital to shareholders makes it a compelling option for patient investors.
This article is for informational purposes only and does not constitute financial advice.
